On 8 May 2026, BeOne Medicines Ltd. approved the award of 25,436 restricted share units (RSUs), equivalent to 330,668 ordinary shares, to 201 employees under its Fourth Amended and Restated 2016 Share Option and Incentive Plan. The new grant represents approximately 0.02% of the company’s total issued shares as of the announcement date.

The RSUs carry no consideration cost to recipients and will vest in four equal tranches—25% on each anniversary of the grantee’s start-date anniversary or, for four specific employees, each anniversary of 30 April 2026—subject to continued employment. Certain termination or change-of-control events could accelerate vesting.

Based on the 8 May 2026 closing price of US$312.12 per American Depositary Share (each ADS represents 13 ordinary shares), the award has a notional market value of approximately US$7.94 million (HK$62.19 million).

The grant does not impose performance targets or clawback provisions, aligning with prevailing market practice and the objectives of the 2016 plan. None of the grantees are directors, chief executives, substantial shareholders, related-entity participants, or service providers exceeding relevant Hong Kong Listing Rules thresholds.

Following this transaction, 61.51 million ordinary shares remain available for future equity awards under the incentive plan, including 20.40 million reserved for the consultant sub-limit.